Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients.
Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients.
复制标题
原发肿瘤位置作为转移性结直肠癌患者一线贝伐珠单抗疗效的预测因素。
DOI：
10.7150/jca.16804
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Xia LP
中科院分区：
文献类型：
--
作者：
He WZ;Liao FX;Jiang C;Kong PF;Yin CX;Yang Q;Qiu HJ;Zhang B;Xia LP
背景资料：已发表的论文报告了关于贝伐单抗有效性与转移性结直肠癌（mCRC）原发肿瘤位置之间相关性的矛盾结果。研究方法：纳入740例接受化疗的mCRC患者（CT组）和244例接受贝伐单抗联合化疗作为一线治疗的患者（CT + B组）。倾向评分分析用于患者分层和匹配。采用Kaplan-Meier曲线和对数秩检验来检测不同的总生存期（OS）。结果如下：仅当原发肿瘤位于右侧结肠时，CT + B组患者的OS与CT组相似（CT + B组为20.2个月，CT组为19.7个月，p = 0.269）。对于左侧结肠癌和直肠癌患者，观察到CT + B组的OS显著长于CT组。结论：我们的数据表明，只有左侧结肠癌或直肠癌患者可以从一线化疗中添加贝伐单抗获得生存益处。
Background: Published papers reported contradictory results about the correlation between bevacizumab effectiveness and primary tumor location of metastatic colorectal cancer (mCRC). Methods: 740 mCRC patients treated with chemotherapy (CT group) and 244 patients treated with bevacizumab plus chemotherapy as first-line setting (CT + B group) were included. Propensity score analyses were used for patients' stratification and matching. Kaplan-Meier curves with log-rank tests were used to detect different overall survival (OS). Results: Patients in CT + B group had similar OS comparing with CT group only when the primary tumor located at right-side colon (20.2 for CT + B versus 19.7 months for CT group, p = 0.269). For left-side colon and rectal cancer patients, significantly longer OS were observed in CT + B than CT group. Conclusion: Our data suggested only patients with left-side colon or rectal cancer could get survival benefit from the addition of bevacizumab to first-line chemotherapy.